Jordyn Sava

Josep M. Llovet, MD, PhD, discussed the updated data from the LEAP-012 trial in intermediate-stage hepatocellular carcinoma.

Janelle Vicens, DNP, APRN, FNP-BC, and Sandra Sepulveda, AGPNP-BC, MSN, BMTCN, discussed what went into developing this Malignant Hematology and Bone Marrow Transplant APP Fellowship.

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed emerging endocrine therapies that are advancing breast cancer treatment.

The FDA accepted the new drug application for TLX101-CDx and granted priority review to the agent in glioma.

John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.

In an interview with Targeted Oncology, Hina Saeed, MD, discussed how AI and radiomics are changing the landscape of radiation oncology.

The new drug application resubmission of rivoceranib/camrelizumab in the first line in unresectable or metastatic hepatocellular carcinoma is supported by the final survival analysis of CARES-310 trial.

The FDA has approved the Ion Torrent Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for treatment with vorasidenib.

The FREEDOM2 study demonstrates that fedratinib is an effective second-line treatment for myelofibrosis after ruxolitinib failure or intolerance.

Antonious Hazim, MD, shares insights on his journey into oncology, his experiences at the Mayo Clinic, and his ongoing research.

The FDA granted galinpepimut-S a rare pediatric disease designation for the treatment of pediatric patients with acute myeloid leukemia.

The 0.09 mg/kg dose group of the phase 1 dose-escalation portion of the Acclaim-3 study in extensive-stage small cell lung cancer is completed.

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors or docetaxel in patients with metastatic non–small cell lung cancer.

In an interview with Targeted Oncology, Omar Nadeem, MD, discussed the first results from the Immuno-PRISM study in patients with high-risk smoldering myeloma.

The phase 3 trial AMPLIFY study plans to test the diagnostic performance of 64Cu-SAR-bisPSMA PET/CT imaging in approximately 220 patients with prostate cancer with biochemical recurrence.

In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.

Eric Cheung, DO, Targeted Oncology’s second 2024 Oncology Icon, discussed his journey in oncology, advances in treatment, and his patient-centered approach to care.

The FDA has approved the WATER IV PCa trial, which will compare the safety and efficacy of Aquablation therapy to radical prostatectomy in patients with localized prostate cancer.

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with pembrolizumab.

Yufei Liu, MD, PhD, discussed the importance of careful data interpretation to accurately assess the efficacy of new treatment options in oncology.

Jacob E. Berchuck, MD, discussed research behind using a blood-based liquid biopsy in prostate cancer and findings presented at the 2024 ESMO Congress.

The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been discontinued.

The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.

In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed a machine learning tool designed to predict local failure after stereotactic radiosurgery for brain metastases.

M. Michele Blackwood, MD, FACS, provided an overview of the significant advancements with personalized medicine with genomic testing in the breast cancer space.

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell lung cancer, based on data from the phase 3 CheckMate 77T trial.

In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer.

In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow and lymphoid irradiation with cyclophosphamide and etoposide in high-risk acute leukemia.

Savita Dandapani, MD, PhD, discussed combining radium-223 and SBRT for metastatic castration-sensitive prostate cancer.

In an interview, Prithviraj Bose, MD, discussed the multiple JAK inhibitors available for the treatment of patients with myeloproliferative neoplasms.